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Introduction 
 
Corticosteroids are the standard component for the treatment of acute lymphoblastic leukemia 
(ALL)and lymphoblastic lymphoma (LBL). The response to corticosteroids during the 
pretreatment phase is essential in defining the risk of ALL and treatment outcome, especially in 
children (1-3)
 
. Corticosteroids are also part of the induction and the maintenance therapy in 
adults (4, 5). Dexamethasone (DXM) is 6.5 times more potent than prednisolone (PDN) as 
measured by conventional glucocorticoid activity, but it shows a 16 fold gain in potency against 
lymphoblasts in vitro, suggesting that dexamethasone might be a more active corticosteroid in the 
treatment of ALL (6-7). The better penetration in the central nervous system (CNS) (8) and the 
enhanced lymphoblastic cytotoxicity might explain the lower bone marrow relapse rate, the lower 
CNS relapse rate and the advantage in event-free survival in children receiving dexamethasone 
(9–11). The attempts to increase its antileukemic effect by increasing the dose of DXM has been 
associated with increased toxicity and early deaths mostly due to severe infections (12).  
Since comparison of DXM versus PND is not available for adult patients with ALL/LBL we 
investigated in this randomized phase trial the antileukemic activity and toxicity of DXM 
compared with PDN.  
Design, Patients and Methods  
Previously untreated adult ALL or LBL  patients were eligible to be entered in this trial. The 
study was approved by the EORTC Protocol Review Committee and by Ethic Committees of the 
participating institutions. The study was conducted in 20 European centers, in accordance with 
the Declaration of Helsinki. The study design is presented in Figure 1. Inclusion criteria were 
absence of prior malignancy except those originating in the skin (non-melanoma) or those considered 
to be cured, absence of severe cardiac, pulmonary, neurological or metabolic disease, adequate liver 
(bilirubin <2 mg/dl) and renal (creatinine <2 mg/dl) function tests (unless considered due to 
leukemic involvement), and HIV negativity. All participants gave their informed consent. 
For remission induction patients were randomized to receive DXM or PDN  together with 
chemotherapy. The first randomization was prospectively stratified by WBC, diagnosis (ALL vs. 
LBL), age (15-19,20-34,35-60, >60 years) and center using a minimization technique. Patients 
who achieved complete or good partial remission were eligible to receive a course of intensive 
consolidation with high dose cytarabine and mitoxantrone (HAM). All patients in complete 
remission (CR) after HAM consolidation underwent   treatment with two courses of consolidation 
consisting of high dose methotrexate and asparaginase (MA).  After MA consolidation patients 50 
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Abstract  
 
 
Background 
Corticosteroids are the standard component for the treatment of ALL and LL patients. 
Our aim was to assess whether dexamethasone (DXM) result in a better outcome than 
Prednisolone (PDN). 
Design and Metdhods 
Adult ALL and LL patients were randomized to receive in induction on days 1-8, 15-22, 
either DXM 8 mg/m
2
 or PDN 60 mg/m
2
. Those who reached complete remission (CR), 
two courses of consolidation (HAM and MA) were administered. Subsequently patient 
younger than 50 years, with a donor, had to receive AlloSCT, whereas the others, either 
autoSCT or high dose maintenance chemotherapy with prophylactic CNS irradiation. 
Randomization was done with a minimization technique. The primary endpoint was 
event-free survival (EFS). Analysis were done by intention to treat.  
Results 
Between August 1995 and October 2003, 325 patients between 15 to 72 years of age 
were randomized to receive either DXM (163 patients) or PDN (162 patients). After 
induction and first consolidation course, 131 (80,4%) patients in DXM group and 
124(76,5%) in PDN group achieved CR. No significant difference was observed between 
the 2 treatment groups regarding EFS: P=0.82, hazard ratio 0.97, 95% confidence interval 
0.75-1.25, the 6-year EFS rates (±SE) were 25.9%(3.6%) vs. 28.7% (3.5%). Disease-Free 
survival (DFS) from CR was similar in DXM and PDN group: hazard ratio1.03, 95% 
confindence interval 0.76-1.40. The 6-year DFS rate was 32.3% (DXM) vs. 37,5% (PDN) 
group, the 6-year cummulative incidence of relapse was 32.3 (DXM) vs. 37.5% (PDN) 
group, the 6-year cumulative incidence of relapse was 49.8% vs. 53.5% (Gray test: 
P=0.30) and of death was 18% vs. 9% (Gray test: P=0.07).  
Conclusions 
In the ALL-4 trial in adult patients, DXM did not show any advantage compared to PDN.  
This study is registered with Clinical Trials gov. number NCT00002700. 
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years of age or less with a sibling donor were assigned to undergo an allogeneic hematopoietic 
stem cell transplantation (allo-SCT), while patients without the sibling donor who were 20 to 60 
years of age were randomized to receive either arm A autologous stem cell transplantation (auto-
SCT) followed by low dose maintenance chemotherapy or arm B high dose maintenance 
chemotherapy with prophylactic CNS irradiation. Both maintenances contained vincristine, 
adriamycine and either DXM (VAD) or PDN (VAP). Patients were eligible for the second 
randomization if the following criteria were fulfilled: CR was achieved after induction and/or 
consolidation treatment, allo-SCT was not planned (see below), absence of very high features 
(mature B cell phenotype, acute undifferentiated leukemia or Philadelphia chromosome positive 
ALL) absence of severe cardiac, pulmonary, neurological and metabolic disease, adequate liver 
(bilirubin < 2mg/dl) and  renal (creatinine <2 mg/dl) function tests, a suitable bone marrow function 
in terms of CFU-GM in vitro growth (more than 2 x 10
4
 cells/kg) -and cellularity (nucleated cells 
more than 2 x 10
8
/
 
kg), with HIV negativity after completion of MA consolidation, and signed 
informed consent. 
Patients between 15 and 19 years of age, without a donor (see below) were eligible for the 2
nd
 
randomization if at least one of the following were present: initial WBC > 30 x 10
9
/l,  initial CNS or 
other extramedullary localization, or if CR was achieved after > day 28. The remaining younger 
patients without high risk features or patient older than 60 years had to receive Arm B. Patients <50 
years old with a HLA-matched (geno and phenotypic) family donor or with existence of family 
donor missmatched for one HLA locus (A, B, or DR) or with a matched unrelated donor (optional), 
together with all the conditions mentionned for the second randomization were eligible for allo-SCT. 
The schedule and dose of cytotoxic drugs and chemotherapy courses are presented in Table 1.  
The recommended conditioning regimen for allo- and auto-SCT was cyclophosphamide (60 
mg/kg on two consecutive days) and total body irradiation fractionated over three days, for a total 
dose of 1200 cGy. The graft versus host disease (GvHD) prophylaxis in most centers was 
cyclosporine and short course of methotrexate (13). T-cell depletion of the allogeneic graft was 
performed in 13 cases by elutriation or by alemtuzumab “in the bag” (14).  
Complete remission was defined as a morphologically normal marrow with less than 5% of blasts 
and normal peripheral blood and differential counts. Partial remission was defined as a treatment 
response with reduction of leukemic marrow blasts for more than 50% of blasts at diagnosis, 
and/or hypoplastic marrow and/or cytopenia of peripheral blood count. Refractory patients were 
defined as patients who did not reach CR after induction and first intensive consolidation. Among 
patients who reached CR, relapse was defined as >5% blasts in bone marrow. A diagnosis of 
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extramedullary relapse was based on tissue diagnosis in case of clinical symptoms or organ or 
tissue infiltration and cerebrospinal fluid cytology in case of meningeal relapse. Risk factors were 
defined according to Gökbuget et al.(15).  
Statistical analysis 
 
The ALL-4 trial was a 2x2 factorial design phase III study evaluating efficacy and toxicity of 
DXM vs. PDN and of auto-SCT followed by low dose maintenance vs. prophylactic CNS 
irradiation with high dose maintenance. The primary endpoint for the comparison DXM vs. PDN 
was event-free survival (EFS). EFS was calculated from the date of CR until the date of first 
relapse or of death in first CR; patients who did not reach CR after induction will be considered 
as events at time 0. By definition all patients who died in CR were considered as cases of 
treatment-related mortality (TRM). The duration of survival was calculated from the date of 
randomization until the date of death; patients still alive were censored at their last follow-up. For 
the comparison of second randomization (auto-SCT and low dose maintenance vs. prophylactic 
CNS irradiation and high dose maintenance) the starting point was the date of randomization. 
This study was powered to detect a 15% treatment difference in the 3-year EFS rates (45% in 
DXM group), corresponding to hazard ratio (HR) of 0.66.  A minimum of 308 patients had to be 
randomized, of whom 192 had to be followed until an event (2-sided alpha=5%, beta=20%). 
Actuarial curves were calculated according to the Kaplan-Meier technique (16). The standard 
errors (SE) of the estimates were computed using the Greenwood formula (16). The estimates of 
the incidence of relapse and of death in CR, and their corresponding standard errors, were 
obtained using the cumulative incidence method, in which the risks of death in CR and of relapse 
were considered as competing risks (16). The statistical significance of differences between 
actuarial curves was tested using the two-tailed log-rank test (16), whereas the Gray test was used 
for the cumulative incidences (17). A Cox proportional hazards model was used to obtain the 
estimate and the 95% confidence interval (CI) of the hazard ratio (HR) of the instantaneous event 
rate in one group compared with in another group, as specified by a given variable, and the Wald 
test was used to determine the prognostic significance (16). This model was also used to 
determine the relative prognostic importance of several factors. The database was frozen in 
August 2007. SAS 9.1 statistical software (SAS Institute Inc, Cary, NC, USA) was used. 
Results 
 
Patient’s characteristic according to the 1
st
 randomization 
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Between August 1995 and October 2003, 325 patients between 15 to 72 years of age with ALL or 
LBL were registered in ALL-4 study and randomized to receive either DXM or PDN. Patient 
characteristics according to the treatment arm are presented in Table 2.  
Distribution of age and sex were similar in both groups; 94% of patients had ALL. The initial of 
CNS infiltration was found in 72 patients and its incidence (22%) was similar in the two 
treatment groups. B-lineage ALL was documented in 65% of the patients by 
immunophenotyping. The majority of the patients (70%) fulfilled the criteria for high risk ALL. 
In 215 (66%) patients cytogenetic analysis was successfully done. Among these patients, in 54 
(25%) cytogenetic analysis was normal, while in 23% of them Ph positive ALL was documented. 
The median follow up was 6.6 years with a range from 0.5 to 11.7 years.   
A total of 77 (23%) patients have been allografted in CR1 and 78 (24%) have been randomized 
for the 2
nd
 question. The impact of the 1
st
 randomization group DXM vs. PDN on the last step of 
treatment was quite minor. Failure, relapse and toxicity were the main reason of stopping therapy 
and 30% of patients finished therapy according to the protocol.  
Treatment outcome 
 
Table 3. summarizes the treatment outcome according to the 1
st
 randomization. The similar CR 
rate was achieved for both groups. A total of 131 (80.4%) patients in DXM group and 124 
(76.5%) patients in PDN group achieved CR rate after induction and first consolidation course.  
There was no difference between DXM vs. PDN with respect to primary resistance, hypoplasia 
and early death. The remission rate for patients with CNS infiltration was practically identical for 
both groups, 6 out of 8 patients in DXM group vs. 6 out of 9 patients in PDN group.  
Among patients who reached CR, the relapse rate was also similar for both groups: 48.9% for 
DXM group vs. 52.4% for PDN group. No significant difference was observed between the 2 
treatment groups regarding EFS P=0.82, hazard ratio 0.97, 95% confidence interval 0.75-1.25, 
the 6-year EFS rates were 25.9% (DXM) vs. 28.7% (PDN) (Fig.2A). 
No significant difference was observed between the 2 treatment groups regarding overall survival 
either: P = 0.45, hazard ratio 1.11, 95% confidence interval 0.85-1.45, 6-year survival rates were 
30.6% (DXM) vs. 35.2% (PDN) (Fig 2B).  
As indicated in Figure 2C, DFS was similar in DXM group vs PDN group: P=0.83, hazard ratio 
1.03, 95% confidence interval 0.76-1.40. The 6-year DFS rates from CR were 32.3% (DXM) vs 
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37.5% (PDN) group. The 6-year cumulative incidence (±SE) of relapse was 49.8% (±4.5%) vs 
53.5% (±4.6%) (Gray test: P=0.30), whereas the 6-year cumulative incidence (±SE) of death was 
18.0% (±3.4%) vs 9.0% (±2.6%) (Gray test: P=0.07).  
A trend for shorter overall survival from CR was found for DXM compared to PDN group: 
P=0.18, hazard ratio 1.24, 95% confidence interval 0.90-1.70, the 6-year rates were 35.2% vs. 
43.7% (Fig. 2D.). Using the Cox model, the trend in disfavor of DXM persisted: the comparison 
DXM vs PDN adjusted for the initial WBC and age yield P=0.11, hazard ratio 1.30, 95% 
confidence interval 0.94-1.79. 
 
Toxicity 
Grade III-IV toxicities according to the randomized steroid group, observed during induction 
therapy and consolidation are given in Table 4.  
 
The incidence of severe toxicities was similar for DXM group and PDN group. A trend for higher 
incidence of hyperglycemia was documented in DXM group. In both treatment arms leukemia 
was the main cause of death (data not shown). In patients who reached CR, 18% (DXM group) vs 
10.5% (PDN group) died without relapse. Most of the mortality was related to allo-SCT. The 
predominant causes of death following allografting were infections, severe GvHD and organ 
toxicity.  
 
Discussion  
 
DXM given as a steroid therapy for adult ALL/LBL in the ALL-4 trial of the EORTC-Leukemia 
Group did not show any benefit in the treatment outcome compared to PDN. Antileukemic 
efficacy did not seem to differ between the DXM and PDN group. Thus, the results of ALL-4 
study did not support the experience from several pediatric studies using historical controls and of 
2 large prospectively randomized clinical trials (18, 19), showing that patients receiving DXM 
have a better outcome. Data reporting that DXM penetrates better in the CNS and has enhanced 
activity against disease (9-11) could not be confirmed in ALL-4 trial. 
Reasons for non superiority of DXM in our trial might be the type of patient treated (adult versus 
children) and the dosages of DXM and PDN. The Children’s Cancer Group trial CCG-1922 (18) 
evaluated the role of DXM compared to PDN in standard risk ALL during induction, 
consolidation and maintenance therapy (< 10 years of age and WBC counts <50x10
9
/L). In a 
daily dose of 6 mg/m
2
 for 28 days they administered to the patients randomized in the DXM arm 
DOI: 10.3324/haematol.2009.018580 
 8
168 mg/m
2 
in the induction phase, 120 mg/m
2
 during the consolidation, 210 mg/m
2
 during the 
delayed intensification (NOTE: also on the PDN arm) and 150 mg/m
2
 during the maintenance 
phase. The daily dose of PDN in induction was 40 mg/m
2
 and the expected total dosages given 
were, respectively, 1160 mg/m
2
, 800 mg/m
2
, and 600 mg/m
2
 per maintenance cycle. They found a 
significant difference in event-free survival at 6 years (85% vs. 77%), but no difference in overall 
survival. Furthermore there was a significant difference in isolated CNS relapse rate and a trend 
to a difference in bone marrow relapse rate in favor of the DXM arm. Patients using DXM 
developed more often myopathy and hyperglycemia. No difference was found in infection 
frequency and severity between both arms.  
In the ALL 97/99 trial of the MRC Childhood Leukemia Working Party (19) standard and high 
risk ALL patients (very high risk excluded) were randomized to receive either PDN or DXM. 
They had to receive a DXM daily dose of 6.5 mg/m
2
 for 28 days, corresponding to a total dose 
182 mg/m
2
 in induction, 130 mg/m
2
 as interim maintenance, 140 mg/m
2
 during delayed 
intensification (NOTE: also in the PRED arm) and 97.5 mg/m
2
 each 12 weeks cycle as 
continuation therapy. In the PDN-arm, the daily dose of PDN was 40 mg/m
2
 and the total dosages 
were 1160 mg/m
2
, 400 mg/m
2
 and 600 mg/m
2
 per maintenance cycle, respectively. They also 
found at 5 years a significant difference in event-free survival in favor of DXM arm (84% vs. 
76%), but not in terms of overall survival. The CNS risk of relapse was significantly decreased 
but not the bone marrow relapse. There was a significant excess of overall toxicity in the DXM 
group due to behavioral problems, myopathy and severe osteopenia, as well as a decreased 
quality of life (20)  but not due to infections. 
The ALL-4 trial included only patients over the age of 18 years. Majority of patients were high 
risk ALL/LBL. A total dose of 112 mg/m
2
 DXM during induction and 320 mg total dose 
(corresponds with 160 – 200 mg/m
2
) during the maintenance phase was administered. The PDN 
dosages were 840 mg/m
2
 and 800 mg total dose (approx. 400-450 mg/m
2
). We found neither 
differences in disease-free and overall survival, nor in relapse incidence and pattern, while a trend 
for higher toxicity was observed in the DXM arm.  
The adult patients in our trial received only 65-70% of the DXM dose reported in the childhood 
ALL trials (18, 19)
 
but they also received a lower total dose of PDN (approx. 70%) than the 
children.  In addition, the type of patients treated differs largely from that of the pediatric trials 
with respect to age and to the percentage of high risk patients. The difference of DXM efficacy in 
children and adult ALL could be also related to a different biology of the disease in children and 
adults (21), and different intensity of treatment protocols used (22). More aggressive 
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chemotherapy together with better prognosis of ALL in children (23, 24), could be of importance 
in predicting better response to steroids.  
From a pilot trial (06/99) of the German Multicenter Study Group for Adult ALL (GMALL) (25)
 
evaluating the efficacy of different dosages of DXM, the authors reported that the “low” dose 
induction schedules of DXM (90 or 120 mg/m
2
 total dose) showed a similarly good antileukemic 
efficacy (CR rate of ~80%) as their higher dose schedule (260 mg/m
2
) whereas the incidence of 
early deaths and severe infections was significantly lower in patients receiving the low total dose 
schedule. Although this is not a randomized trial, this study has already led to a preference for 
DXM instead of PDN in Germany. In the ALL-4 study the patients received 112 mg/m
2
 total dose 
of DXM during induction, which is similar to the “low” dose group in the GMALL study. The 
CR rate is similar (78%) but the incidence of serious infections and early deaths is higher 
compare to the data of the “low “dose schedule of DXM in the GMALL pilot study.  
Serious toxicity in adults could strongly influence the outcome and thus change the results of 
steroid therapy. Some data clearly showed that treatment related toxicity is significantly higher in 
older patients (26).
 
In addition it seems that intensive DXM therapy is more immunosuppressive 
and hence more frequently associated with serious infections than PDN in ALL trials (12, 27, 28). 
On the other hand steroid toxicity in adult could not be compared to the steroid toxicity in 
children because of the different postremission treatment strategy. The majority of adult patients 
who are eligible for allo-SCT underwent allotransplant in 1
st
 CR. Most of the children in 1
st
 CR 
received intensified chemotherapy courses and maintenance chemotherapy which are quite 
tolerable in this age group of patients. Contrary to that, Allo-SCT performed with standard 
conditioning is still associated with high mortality rate ranging from 15% to 30% (29, 30). 
Recently it was shown that polymorphism of genes involved in corticosteroid response is 
important predictor of  it's toxicity. Glutathione-S-transferase-M1 genotype might influence the 
severity of infection in childhood ALL (31)  
In conclusion DXM as a steroid therapy for adult patients with ALL/LBL at the dose given in the 
ALL-4 trial did not show any advantage compared to PDN. The toxicity of both drugs during 
induction therapy and consolidation was similar.  
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Table 1. Scheme of the ALL-4 Protocol.
Months Registration 
1 R1 
 
DXM 8 mg/m2 i.v. or p.o.                                                           PDN 60 mg/m2 i.v. or p.o. 
days 1-8, 15-22;                                                                           days 1-8, 15-22; 
                         Daunorubicine 30 mg/m2 i.v. days 1,2,3, 15,16: 
                         Cyclophosphamide 750 mg/m2 i.v. days 1,8; 
                         Vincristine 2 mg i.v. days 1,8,15,23; 
                         Methotrexate (MTX) 15 mg i.t. 1,8,15,22,28;  
2 Consolidation Therapy „HAM“ 
High-dose cytarabine 1 g/m2 i.v. as 2 hours infusion every 12 hours for 6 days 
Mitoxantrone 10 mg/m2 i.v. for 3 days   
3 Consolidation Therapy „MA“ 
MTX 1500 mg/m2 i.v. in 30 minutes days 65,80 and folinic acid rescue 
Asparaginase (E. coli) 10.000 IU/m2 in i hour infusion or i.m. days 66,81 
                                               R2 
 
                                                                                                             Allo-SCT 
        Arm  A                                                            Arm B  
Auto-SCT                   CC – Cyclophosphamide 1 g/m2 i.v. day 1 
                                              Cytarabine 500 mg/m2 in 24-hour infusion, day 1 
                                              6-MP 60 mg/m2/day orally + MTX 15 mg/m2/week 
                                              orally starting 1 week after CC and stopping  one 
                                              week before the next course 
  
   MTX   i.t.                             CNS irradiation 18 Gy 
                                               MTX i.t.* first day of irradiation 
                                     MA -  Methotrexate 1500 mg/m2 i.v. on day 1  
                                               Asparaginase 10.000 IU/m2 i.v. or i.m. 
  
                                      CC 
 VAD** or VAP**       VAD/VAP 
    + MTX i.t.*                        Vincristine 0,4 mg/day i.v. days 1-4 
                                               Adriamycin 12 mg/m2/day i.v., days 1-4  
                                               DXM 40 mg/day days 1-4 or PDN 100 mg/day, days 1-4 
                                               MTX i.t.* day 1  
    VAD or VAP                                          VAD or VAP 
       + MTX i.t.                                             + MTX i.t.  
   6-MP + MTX***                                             MA 
   6-MP + MTX                                                   CC 
   6-MP + MTX                                                   MA 
   6-MP + MTX                                                   CC 
   6-MP + MTX                                                   MA 
   6-MP + MTX                                                   CC 
   6-MP + MTX                                                   MA 
   6-MP + MTX                                                   CC 
   6-MP + MTX                                                   MA 
   6-MP + MTX                                                   CC 
   6-MP + MTX                                                   MA 
   6-MP + MTX                                                   CC 
   6-MP + MTX                                           stop treatment 
  stop treatment 
* MTX i.t. = methotrexate i.t. (same dose as in induction therapy) 
** VAD/VAP same dose as in arm B 
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Table 2. Patient's characteristics according to the 1
st
 randomization. 
 
 Dexamethazone 
n=163 (100%) 
Prednisolone 
n=162 (100%) 
Sex (n, %)   
 Male 90 (55) 97 (60) 
 Female 73 (45) 65 (40) 
Age* (years)   
 Median (range) 32 (15–68) 33.5 (15–72) 
 15 to <20 (n, %) 30 (18) 30 (19) 
 20 to <35 (n, %) 57 (35) 55 (34) 
 35 to <61 (n, %) 68 (42) 69 (43) 
  61 (n, %) 8 (5) 8 (5) 
Disease* (n, %)   
 ALL 153 (94) 152 (94) 
 NHL 10 (6) 10 (6) 
WBC* (x 10
9
/l)   
 Median (range) 11.4 (0.8 - 373) 13.6 (0.9 - 934) 
 < 30 (n, %) 109 (67) 107 (66) 
 30 to <= 100 (n, %) 31 (19) 32 (20) 
 > 100 (n, %) 23 (14) 23 (14) 
Immunophenotype (n, %)   
 B-lineage (n, %) 106 (65) 111 (69) 
 T-lineage (n, %) 50 (31) 40 (25) 
 Biphenotypic (n, %) 5 (3) 4 (2) 
 AUL (n, %) 2 (1) 6 (4) 
 Unknown (n, %) 0 (0) 1 (1) 
Cytogenetics (n, %)   
 Failure (n, %) 19 (12) 15 (9) 
 NN (n, %) 27 (17) 28 (17) 
 Good risk (n, %)* 31 (19) 23 (14) 
 Presence of t(4;11) (n, %) 2 (1) 5 (3) 
 Presence of t(9;22)** (n, %) 29 (18) 28 (17) 
 Other bad risk (n, %) 18 (11) 13 (8) 
 Other abnormalities (n, %) 6 (4) 5 (3) 
 Unknown (n, %) 35 (22) 41 (25) 
Extramedulary involvement (n, %)   
 No (n, %) 117 (72) 115 (71) 
 CNS (n, %) 37 (23) 35 (22) 
 Other involvement (n, %) 9 (6) 12 (7) 
* Good risk: hyperdiploidy, presence of 9p-, t(10;14) 
**  and/or presence of BCR/ABL, detected by RT-PCR 
*** Other bad risk cytogenetics: hypodiploidy (<30), presence of t(8;14), complex abnormalities 
(>= 5 chromosomal abnormalities, excluding those patients with established translocations)  
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Table 3. Treatment outcome for all patients and for patients randomized to receive DXM 
or PDN.
 
 
Variable 
Dexamethazone 
n=163 (%) 
Prednisolone 
n=
 
162 (%) 
Overall response  
    CR 
    PR 
    Resistance 
    Hypoplasia 
    Early Death 
    Not valuable    
 
131 (80.4) 
5 (3.1) 
6 (3.7) 
5 (3.1) 
14 ( 9.8) 
2 ( 1.2) 
 
124 (76.5) 
11 (6.8) 
   7 (4.3) 
   4 (2.5) 
  13 (8.0) 
    3 (1.9)  
DFS status 
    CCR 
    Relapse 
       BM only 
       CNS relapse only 
       CNS+BM 
       others 
    TRM** 
        Infection 
       Hemorrhages 
       GvHD 
       Other 
 
43 [32.8] 
64 [48.9] 
   44 [33.6] 
   3 [2.3] 
   6 [4.6] 
   11 [8.4] 
24 [18.3] 
11 
1 
5 
7 
 
46 [37.1] 
65 [52.4]  
   48 [38.7] 
   5 [4.0] 
   5 [4.0] 
   7 [5.8] 
 13 [10.5] 
7 
3 
1 
2 
Survival status 
    Alive 
    Dead 
       Leukemia 
       Toxicity 
       Both 
       Other  
 
50 (30.7)  
113 (69.3) 
  51 (31.3) 
  43 (26.4) 
  8 (4.9) 
  11 (6.7) 
 
58 (35.8)  
104 (64.2)  
  56 (34.6) 
  31 (19.1) 
  7 (4.3) 
  10 (6.2) 
* CNSCR – CR for patients with CNS infiltration at diagnosis 
**: after AlloSCT: 14 (2 in Ph+ pts) vs 9 (1 in Ph+) 
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Table 4. Toxicity grade III-IV according to 1
st
 randomization (DXM vs. PDN) and 
treatment phase. 
 
Induction course  
Variable DXM  
N=114 (100%)     
PDN  
N=112 (100%)           
 
Hemorrhages 
 
Presence of hyperglycemia 
 
Insomnia*** / neurotoxicity 
 
Infection 
 
Others*  
 
 
6 (5.2) 
 
19 (16.7) 
 
5 (4.4) 
 
62 (54.4) 
 
41 (36.0) 
 
8 (7.2) 
 
12 (10.7) 
 
4 (3.6) 
 
67 (59.8) 
 
39 (34.8) 
Consolidation course 
Variable DXM  
N=68 (100%)       
PDN  
N=61 (100%)             
 
Hemorrhages 
 
Presence of hyperglycemia 
 
Insomnia*** / neurotoxicity 
 
Infection 
 
Others*  
 
 
3 (4.4) 
 
NA** 
 
4 (5.9) 
 
57 (83.8) 
 
31 (45.6) 
 
8 (7.2) 
 
NA** 
 
3 (6.5) 
 
48 (78.8) 
 
24 (39.3) 
 
 
* Other clinical relevant complications: nephrotoxicity, cardiotoxicity etc.  
** NA – not applicable (information not collected) 
***: recorded only during induction 
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Figure 1. EORTC ALL-4 protocol: study design. 
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Figure 2. The 6-year of EFS (A) and overall survival (B) , DFS from CR  (C) and 
survival from CR (D)  according to the randomization DXM vs. PDN N = total number 
of patients; O = observed number of events; SE:  Standard error (%).  
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